Abstract
Autotaxin (ATX or NPP2) is a newly discovered secreted glycoprotein lyso-phospholipase D (lysoPLD). Its main role is the lysoPLD activity, which transforms lyso-phosphatidylcholine (LPC) into lyso-phosphatidic acid (LPA). ATX contributes to tumor progression, inflammation, obesity and diabetes and constitutes a target for drug design. Various synthetic phospholipid analogues have been explored as ATX inhibitors. However, potent and selective non-lipid inhibitors of ATX are currently not available. Some new ATX inhibitors have been subjected to a Quantitative-Structure Activity Relationships (QSAR) analysis. CMR represents the calculated molar refractivity of the molecules and seems to govern the ATX inhibition. Steric factors are obviously important. No role for lipophilicity was found. Electronic parameters are not found to be present.
Keywords: Boronic Acid based Autotaxin Inhibitors, Hydrophobicity, Molar Refractivity, QSAR, lyso-phosphatidic, cell proliferation, phospholipase, macromolecular systems
Letters in Drug Design & Discovery
Title:Boronic Acid Based Inhibitors of Autotaxin: Understanding their Biological Role in Terms of Quantitative Structure Activity Relationships (QSAR)
Volume: 10 Issue: 1
Author(s): Sotirios Katsamakas and Dimitra Hadjipavlou-Litina
Affiliation:
Keywords: Boronic Acid based Autotaxin Inhibitors, Hydrophobicity, Molar Refractivity, QSAR, lyso-phosphatidic, cell proliferation, phospholipase, macromolecular systems
Abstract: Autotaxin (ATX or NPP2) is a newly discovered secreted glycoprotein lyso-phospholipase D (lysoPLD). Its main role is the lysoPLD activity, which transforms lyso-phosphatidylcholine (LPC) into lyso-phosphatidic acid (LPA). ATX contributes to tumor progression, inflammation, obesity and diabetes and constitutes a target for drug design. Various synthetic phospholipid analogues have been explored as ATX inhibitors. However, potent and selective non-lipid inhibitors of ATX are currently not available. Some new ATX inhibitors have been subjected to a Quantitative-Structure Activity Relationships (QSAR) analysis. CMR represents the calculated molar refractivity of the molecules and seems to govern the ATX inhibition. Steric factors are obviously important. No role for lipophilicity was found. Electronic parameters are not found to be present.
Export Options
About this article
Cite this article as:
Katsamakas Sotirios and Hadjipavlou-Litina Dimitra, Boronic Acid Based Inhibitors of Autotaxin: Understanding their Biological Role in Terms of Quantitative Structure Activity Relationships (QSAR), Letters in Drug Design & Discovery 2013; 10 (1) . https://dx.doi.org/10.2174/1570180811309010011
DOI https://dx.doi.org/10.2174/1570180811309010011 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms of Melatonin in Alleviating Alzheimer’s Disease
Current Neuropharmacology Poly (ADP-Ribosyl) Polymerase 1 Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery The Relation Between the Chemical Structure of Flavonoids and Their Estrogen-Like Activities
Current Medicinal Chemistry Immunogenicity and Tumorigenicity of Pluripotent Stem Cells and their Derivatives: Genetic and Epigenetic Perspectives
Current Stem Cell Research & Therapy The Effect of Lipoic Acid on Macro and Trace Metal Levels in Living Tissues Exposed to Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Understanding Epithelial-Mesenchymal Transition may Reveal Novel Therapeutic Targets for Oral Squamous Cell Carcinoma
Current Cancer Therapy Reviews Design, Synthesis, Molecular Docking and Biological Evaluation of 1-(benzo[d]thiazol-2-ylamino)(phenyl)methyl)naphthalen-2-ol Derivatives as Antiproliferative Agents
Letters in Organic Chemistry Targeting Heat Shock Proteins 70/90 and Proteasome for Cancer Therapy
Current Medicinal Chemistry Hepatoprotective Evidence of Hydroxytyrosol Against Non-Alcoholic Fatty Liver in Animal Models
Current Nutraceuticals Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications
Current Drug Targets Regulatory Effects of N-3 PUFAs on Pancreatic β-cells and Insulin-sensitive Tissues
Current Drug Metabolism From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets Cytochromes P450 in the Bioactivation of Chemicals
Current Topics in Medicinal Chemistry Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer
Current Medicinal Chemistry Rate-Determining and Rate-Limiting Steps in the Clearance and Excretion of a Potent and Selective p21-Activated Kinase Inhibitor: A Case Study of Rapid Hepatic Uptake and Slow Elimination in Rat
Drug Metabolism Letters Hematological Malignancies and Pregnancy. A Brief Review
Reviews on Recent Clinical Trials Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics Long Non-coding RNA HOTAIR Promotes Parkinson's Disease Induced by MPTP Through up-regulating the Expression of LRRK2
Current Neurovascular Research Nano Drug Delivery in Treatment of Oral Cancer, A Review of the Literature
Current Drug Targets Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance
Current Cancer Drug Targets